ClinicalTrials.gg
CompletedNCT03706040Updated Nov 18, 2021Results posted

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Placebo and Risankizumab in Dermatitis, sponsored by AbbVie. Completed at 65 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-18.

Primary conditionDermatitis, AtopicRegistry: DermatitisReclassifiedWhy we changed it
Registry
Dermatitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dermatitis, Atopic
Why
  1. The study's title name Dermatitis, Atopic, a narrower term within Dermatitis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Dermatitis, Atopic by AbbVie — 3 open to participants now, 12 under way, 4 of them phase 3. Dermatitis, Atopic · AbbVie.

Enrollment
13th of 22
172 · median 228
Started
2018
with 4 others
Phase 2
6 of 34
2 open now
Registered
7th of 34
by date

Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 13th largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 2, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 34 studies in Dermatitis, Atopic by AbbVie are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Dermatitis, Atopic by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.

Read the detailed description

This study includes a screening period of up to 35 days, a 16-week double-blind treatment period (Period A), and a 36-week double-blind treatment period (Period B).

Participants who meet eligibility criteria will be randomized at Baseline in a 2:2:1 ratio to one of 3 treatment groups: (1) risankizumab 150 mg, (2) risankizumab 300 mg, or (3) matching placebo. Randomization will be stratified by Baseline disease severity (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]) and geographic region (Japan versus rest of world).

At Week 16, participants in the placebo group will be re-randomized in a 1:1 ratio to receive either risankizumab 150 mg or 300 mg for the remainder of the study. Participants originally randomized to the risankizumab 150 mg or 300 mg arms will stay on their previously-assigned treatment through the end of the study.

03

Conditions studied

  • Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis, Atopic dermatitis (atopic eczema)
04

In context

Dermatitis, Atopic Reclassified

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's enrollment of 172 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Dermatitis, Atopic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dermatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults who are ≥ 18 years old and, where locally permissible and approved, adolescent subjects who are at least 12 years old
  • a diagnosis of atopic dermatitis (AD) with onset of symptoms at least 2 years prior to Baseline and subject meets Hanifin and Rajka criteria
  • moderate to severe AD at the Baseline Visit
  • history of inadequate response to previous topical and/or topical calcineurin inhibitor treatments or a medical inability to receive these treatments

Exclusion criteria

Exclusion Criteria:

  • prior exposure to any biologic immunomodulatory agent or Janus kinase (JAK) inhibitor
  • concurrent treatment with systemic therapy for AD (biologic or non-biologic) or topical and/or phototherapy treatments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
172 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.

    Biological: Placebo · Biological: Risankizumab

  • Experimental
    Risankizumab 150 mg

    Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.

    Biological: Risankizumab

  • Experimental
    Risankizumab 300 mg

    Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.

    Biological: Risankizumab

Interventions

  • BiologicalPlacebo

    subcutaneous (SC) injection

  • BiologicalRisankizumab

    subcutaneous (SC) injection

    Also known as: ABBV-066, BI 655066

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 16

    Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

    Time frame: Baseline and Week 16

  2. Percentage of Participants Who Achieved a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 16

  3. Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  4. Percent Change From Baseline in EASI Score at Week 28 and Week 52

    EASI is used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected and the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling), scratching, and lichenification (lined skin, prurigo nodules). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement. LS means were calculated from an analysis of covariance (ANCOVA) model with Baseline, treatment and vIGA-AD categories in the model.

    Time frame: Baseline and Weeks 28 and 52

  5. Percentage of Participants Who Achieved an EASI 75 Response at Week 28 and Week 52

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Weeks 28 and 52

  6. Percentage of Participants Who Achieved an EASI 50 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  7. Percentage of Participants Who Achieved an EASI 50 Response at Week 28 and Week 52

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Weeks 28 and 52

  8. Percentage of Participants Who Achieved an EASI 90 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline, Week 16

  9. Percentage of Participants Who Achieved an EASI 90 Response at Week 28 and Week 52

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Weeks 28 and 52

  10. Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 28 and Week 52

    Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

    Time frame: Baseline and Weeks 28 and 52

  11. Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16

    Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  12. Change From Baseline in Percentage of BSA Affected by Atopic Dermatitis at Weeks 28 and 52

    Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.

    Time frame: Baseline and Weeks 28 and 52

  13. Percentage of Participants Who Achieved a 50% Improvement in SCORing Atopic Dermatitis (SCORAD) Score (SCORAD 50) at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).

    Time frame: Baseline, Week 16

  14. Percentage of Participants Who Achieved a SCORAD 50 Response at Week 28 and Week 52

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).

    Time frame: Baseline and Weeks 28 and 52

  15. Percentage of Participants Who Achieved a SCORAD 75 Response at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.

    Time frame: Baseline and Week 16

  16. Percentage of Participants Who Achieved a SCORAD 75 Response at Week 28 and Week 52

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.

    Time frame: Baseline and Weeks 28 and 52

  17. Percentage of Participants Who Achieved a SCORAD 90 Response at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.

    Time frame: Baseline and Week 16

  18. Percentage of Participants Who Achieved a SCORAD 90 Response at Week 28 and Week 52

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.

    Time frame: Baseline and Weeks 28 and 52

  19. Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) Score of "0" or "1" at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.

    Time frame: Week 16

  20. Percentage of Participants Who Achieved a DLQI Score of "0" or "1" at Week 28 and Week 52

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.

    Time frame: Weeks 28 and 52

  21. Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of "0" or "1" at Week 16

    The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.

    Time frame: Week 16

  22. Percentage of Participants Who Achieved a CDLQI Score of "0" or "1" at Week 28 and Week 52

    The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.

    Time frame: Weeks 28 and 52

  23. Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 16 Among Those With a DLQI ≥ 4 at Baseline

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).

    Time frame: Baseline and Week 16

  24. Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 28 and Week 52 Among Those With a DLQI ≥ 4 at Baseline

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).

    Time frame: Baseline and Weeks 28 and 52

  25. Change From Baseline in DLQI Score at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  26. Change From Baseline in DLQI Score at Week 28 and Week 52

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA model with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.

    Time frame: Baseline and Weeks 28 and 52

  27. Change From Baseline in CDLQI Score at Week 16

    The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit.

    Time frame: Baseline and Week 16

  28. Change From Baseline in CDLQI Score at Week 28 and Week 52

    The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit. LS means were calculated from ANCOVA with Baseline and treatment in the model.

    Time frame: Baseline and Weeks 28 and 52

  29. Change From Baseline in Worst Pruritus Numerical Rating Scale at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  30. Change From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.

    Time frame: Baseline and Weeks 28 and 52

  31. Percentage of Participants Who Achieved a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Weeks 28 and 52

08

Results

Posted Nov 18, 2021

Participant flow

Adults and adolescents with moderate to severe atopic dermatitis (AD) with onset of symptoms at least 2 years before the Baseline visit were enrolled at 50 sites in the United States, Canada, Japan, and Australia. The study included a 16-week double-blind treatment period (Period A) followed by a 36-week double-blind treatment period (Period B).

Period A (Week 0 to Week 16)
Participant flow — Period A (Week 0 to Week 16)
MilestonePeriod A: PlaceboPeriod A: Risankizumab 150 mgPeriod A: Risankizumab 300 mgPeriod B: Placebo / Risankizumab 150 mgPeriod B: Placebo / Risankizumab 300 mgPeriod B: Risankizumab 150 mg / Risankizumab 150 mgPeriod B: Risankizumab 300 mg / Risankizumab 300 mg
Started3469690000
Received study drug3469690000
Completed2561580000
Not completed98110000
Withdrew: Adverse event3210000
Withdrew: Withdrew consent3540000
Withdrew: Lost to follow-up1140000
Withdrew: Other2020000
Period B (Week 16 to Week 52)
Participant flow — Period B (Week 16 to Week 52)
MilestonePeriod A: PlaceboPeriod A: Risankizumab 150 mgPeriod A: Risankizumab 300 mgPeriod B: Placebo / Risankizumab 150 mgPeriod B: Placebo / Risankizumab 300 mgPeriod B: Risankizumab 150 mg / Risankizumab 150 mgPeriod B: Risankizumab 300 mg / Risankizumab 300 mg
Started00013126158
Received study drug00013116157
Completed000533330
Not completed000892828
Withdrew: Adverse event0001230
Withdrew: Withdrew consent00032110
Withdrew: Lost to follow-up0000011
Withdrew: Other000452317

Outcome measures

PrimaryPercentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 1611.8 (0.9 to 22.6)24.6 (14.5 to 34.8)21.7 (12.0 to 31.5)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.084 · Adjusted difference: 13.0 · 95% CI -1.7 to 27.7Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.179 · Adjusted difference: 10.0 · 95% CI -4.6 to 24.6Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 16

Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 165.9 (0.0 to 13.8)14.5 (6.2 to 22.8)5.8 (0.3 to 11.3)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.129 · Adjusted difference: 8.7 · 95% CI -2.5 to 20.0Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.994 · Adjusted difference: -0.0 · 95% CI -9.4 to 9.4Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 160 (NA to NA)13.6 (5.4 to 21.9)15.2 (6.5 to 23.8)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted difference: 13.7 · 95% CI 5.4 to 22.1Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 15.3 · 95% CI 6.6 to 24.0Between Group Difference = Risankizumab - Placebo
SecondaryPercent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in EASI Score at Week 16
percent changePlaceboRisankizumab 150 mgRisankizumab 300 mg
Percent Change From Baseline in EASI Score at Week 16-28.54 ± 9.378-38.86 ± 5.989-45.39 ± 6.351
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Mixed Effect Model Repeated Measurement · p = 0.353 · Least squares (ls) mean difference: -10.32 · 95% CI -32.25 to 11.61Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Mixed Effect Model Repeated Measurement · p = 0.139 · Ls mean difference: -16.86 · 95% CI -39.24 to 5.53Between Group Difference = Risankizumab - Placebo
SecondaryPercent Change From Baseline in EASI Score at Week 28 and Week 52

EASI is used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected and the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling), scratching, and lichenification (lined skin, prurigo nodules). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement. LS means were calculated from an analysis of covariance (ANCOVA) model with Baseline, treatment and vIGA-AD categories in the model.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in EASI Score at Week 28 and Week 52
percent changePlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 28-58.60 ± 12.091-59.81 ± 14.956-62.44 ± 5.065-63.77 ± 5.051
Week 52-31.39 ± 12.979-76.75 ± 14.199-67.47 ± 4.663-62.70 ± 4.875
SecondaryPercentage of Participants Who Achieved an EASI 75 Response at Week 28 and Week 52

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 75 Response at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2837.5 (4.0 to 71.0)0 (NA to NA)53.3 (38.8 to 67.9)41.9 (27.1 to 56.6)
Week 520 (NA to NA)75.0 (32.6 to 100.0)43.2 (27.3 to 59.2)45.5 (28.5 to 62.4)
SecondaryPercentage of Participants Who Achieved an EASI 50 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 50 Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved an EASI 50 Response at Week 1629.4 (14.1 to 44.7)42.0 (30.4 to 53.7)34.8 (23.5 to 46.0)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.171 · Adjusted difference: 12.9 · 95% CI -5.6 to 31.4Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.552 · Adjusted difference: 5.7 · 95% CI -13.1 to 24.5Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved an EASI 50 Response at Week 28 and Week 52

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 50 response is defined as at least a 50% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 50 Response at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2875.0 (45.0 to 100.0)80.0 (44.9 to 100.0)73.3 (60.4 to 86.3)74.4 (61.4 to 87.5)
Week 5240.0 (0.0 to 82.9)75.0 (32.6 to 100.0)78.4 (65.1 to 91.6)72.7 (57.5 to 87.9)
SecondaryPercentage of Participants Who Achieved an EASI 90 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 90 Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved an EASI 90 Response at Week 162.9 (0.0 to 8.6)14.5 (6.2 to 22.8)8.7 (2.0 to 15.3)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.022 · Adjusted difference: 11.6 · 95% CI 1.7 to 21.6Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.192 · Adjusted difference: 5.8 · 95% CI -2.9 to 14.4Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved an EASI 90 Response at Week 28 and Week 52

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 90 Response at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2825.0 (0.0 to 55.0)0 (NA to NA)26.7 (13.7 to 39.6)27.9 (14.5 to 41.3)
Week 520 (NA to NA)0 (NA to NA)24.3 (10.5 to 38.1)18.2 (5.0 to 31.3)
SecondaryPercentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 28 and Week 52

Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) was used to assess the severity of AD based on lesion appearance on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a vIGA-AD Score of "0" or "1" With a Reduction From Baseline of ≥ 2 Points at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 280 (NA to NA)0 (NA to NA)22.2 (10.1 to 34.4)25.6 (12.5 to 38.6)
Week 520 (NA to NA)0 (NA to NA)24.3 (10.5 to 38.1)21.2 (7.3 to 35.2)
SecondaryChange From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16

Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percentage of body surface area
Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16
percentage of body surface areaPlaceboRisankizumab 150 mgRisankizumab 300 mg
Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16-7.41 ± 3.813-13.64 ± 2.429-13.27 ± 2.569
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Mixed Effect Model Repeated Measurement · p = 0.169 · Ls mean difference: -6.24 · 95% CI -15.15 to 2.68Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Mixed Effect Model Repeated Measurement · p = 0.204 · Ls mean difference: -5.86 · 95% CI -14.94 to 3.22Between Group Difference = Risankizumab - Placebo
SecondaryChange From Baseline in Percentage of BSA Affected by Atopic Dermatitis at Weeks 28 and 52

Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Least squares mean · percentage of body surface area
Change From Baseline in Percentage of BSA Affected by Atopic Dermatitis at Weeks 28 and 52
percentage of body surface areaPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 28-20.07 ± 5.843-11.90 ± 7.294-23.23 ± 2.438-23.22 ± 2.443
Week 52-0.86 ± 6.525-30.23 ± 7.316-29.26 ± 2.400-22.14 ± 2.510
SecondaryPercentage of Participants Who Achieved a 50% Improvement in SCORing Atopic Dermatitis (SCORAD) Score (SCORAD 50) at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 50% Improvement in SCORing Atopic Dermatitis (SCORAD) Score (SCORAD 50) at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a 50% Improvement in SCORing Atopic Dermatitis (SCORAD) Score (SCORAD 50) at Week 1618.0 (5.0 to 31.1)24.6 (14.5 to 34.8)13.0 (5.1 to 21.0)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.422 · Adjusted difference: 6.7 · 95% CI -9.7 to 23.1Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.505 · Adjusted difference: -5.2 · 95% CI -20.3 to 10.0Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a SCORAD 50 Response at Week 28 and Week 52

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 50 Response at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2844.4 (12.0 to 76.9)20.0 (0.0 to 55.1)47.8 (33.4 to 62.3)37.2 (22.8 to 51.7)
Week 520 (NA to NA)50.0 (1.0 to 99.0)52.6 (36.8 to 68.5)35.1 (19.8 to 50.5)
SecondaryPercentage of Participants Who Achieved a SCORAD 75 Response at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 75 Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a SCORAD 75 Response at Week 160 (NA to NA)10.1 (3.0 to 17.3)2.9 (0.0 to 6.9)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.005 · Adjusted difference: 10.1 · 95% CI 3.0 to 17.3Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.151 · Adjusted difference: 2.9 · 95% CI -1.1 to 6.8Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a SCORAD 75 Response at Week 28 and Week 52

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as at least a 75% reduction (improvement) from Baseline in SCORAD score.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 75 Response at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2811.1 (0.0 to 31.6)0 (NA to NA)23.9 (11.6 to 36.2)11.6 (2.0 to 21.2)
Week 520 (NA to NA)0 (NA to NA)21.1 (8.1 to 34.0)13.5 (2.5 to 24.5)
SecondaryPercentage of Participants Who Achieved a SCORAD 90 Response at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 90 Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a SCORAD 90 Response at Week 160 (NA to NA)5.8 (0.3 to 11.3)1.4 (0.0 to 4.3)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.035 · Adjusted difference: 5.9 · 95% CI 0.4 to 11.3Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.311 · Adjusted difference: 1.5 · 95% CI -1.4 to 4.4Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a SCORAD 90 Response at Week 28 and Week 52

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as at least a 90% reduction (improvement) from Baseline in SCORAD score.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 90 Response at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 280 (NA to NA)0 (NA to NA)6.5 (0.0 to 13.7)4.7 (0.0 to 10.9)
Week 520 (NA to NA)0 (NA to NA)15.8 (4.2 to 27.4)10.8 (0.8 to 20.8)
SecondaryPercentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) Score of "0" or "1" at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) Score of "0" or "1" at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) Score of "0" or "1" at Week 169.0 (0.0 to 18.8)8.7 (2.0 to 15.3)5.8 (0.3 to 11.3)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.965 · Adjusted difference: -0.3 · 95% CI -12.0 to 11.5Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.583 · Adjusted difference: -3.1 · 95% CI -14.3 to 8.1Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a DLQI Score of "0" or "1" at Week 28 and Week 52

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all.

Time frame:
Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DLQI Score of "0" or "1" at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2822.2 (0.0 to 49.4)20.0 (0.0 to 55.1)16.3 (6.0 to 26.7)13.6 (3.5 to 23.8)
Week 5220.0 (0.0 to 55.1)25.0 (0.0 to 67.4)13.9 (2.6 to 25.2)15.6 (3.0 to 28.2)
SecondaryPercentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of "0" or "1" at Week 16

The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of "0" or "1" at Week 16
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a Children's Dermatology Life Quality Index (CDLQI) Score of "0" or "1" at Week 16—00
SecondaryPercentage of Participants Who Achieved a CDLQI Score of "0" or "1" at Week 28 and Week 52

The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. In this study, the CDLQI was administered to participants who were \< 16 years old at Baseline.

Time frame:
Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a CDLQI Score of "0" or "1" at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 28——0—
SecondaryPercentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 16 Among Those With a DLQI ≥ 4 at Baseline

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 16 Among Those With a DLQI ≥ 4 at Baseline
percentage of participantsPlaceboRisankizumab 150 mgRisankizumab 300 mg
Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 16 Among Those With a DLQI ≥ 4 at Baseline25.6 (10.3 to 41.0)31.3 (19.9 to 42.6)37.5 (25.6 to 49.4)
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Cochran-Mantel-Haenszel · p = 0.539 · Adjusted difference: 5.9 · 95% CI -13.0 to 24.9Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Cochran-Mantel-Haenszel · p = 0.213 · Adjusted difference: 12.2 · 95% CI -7.0 to 31.5Between Group Difference = Risankizumab - Placebo
SecondaryPercentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 28 and Week 52 Among Those With a DLQI ≥ 4 at Baseline

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A change in DLQI score of at least 4 points is considered the minimum clinically important difference (MCID).

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Reduction in DLQI of ≥ 4 Points From Baseline at Week 28 and Week 52 Among Those With a DLQI ≥ 4 at Baseline
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2877.8 (50.6 to 100.0)40.0 (0.0 to 82.9)66.7 (52.9 to 80.4)68.3 (54.0 to 82.5)
Week 5260.0 (17.1 to 100.0)50.0 (1.0 to 99.0)63.6 (47.2 to 80.0)66.7 (49.8 to 83.5)
SecondaryChange From Baseline in DLQI Score at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in DLQI Score at Week 16
score on a scalePlaceboRisankizumab 150 mgRisankizumab 300 mg
Change From Baseline in DLQI Score at Week 16-3.4 ± 1.55-3.4 ± 0.95-4.4 ± 1.03
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Mixed Effect Model Repeated Measurement · p = 0.988 · Ls mean difference: 0.0 · 95% CI -3.6 to 3.6Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Mixed Effect Model Repeated Measurement · p = 0.594 · Ls mean difference: -1.0 · 95% CI -4.7 to 2.7Between Group Difference = Risankizumab - Placebo
SecondaryChange From Baseline in DLQI Score at Week 28 and Week 52

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA model with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in DLQI Score at Week 28 and Week 52
score on a scalePlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 28-8.0 ± 2.06-5.3 ± 2.69-7.1 ± 0.87-7.3 ± 0.93
Week 52-4.5 ± 2.99-5.0 ± 3.30-7.7 ± 1.11-6.5 ± 1.18
SecondaryChange From Baseline in CDLQI Score at Week 16

The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in CDLQI Score at Week 16
score on a scalePlaceboRisankizumab 150 mgRisankizumab 300 mg
Change From Baseline in CDLQI Score at Week 16—-2.0 ± NA—
SecondaryChange From Baseline in CDLQI Score at Week 28 and Week 52

The CDLQI is a 10-item, validated questionnaire used to assess the impact of AD disease symptoms and treatment on QoL. The CDLQI has been validated for use in individuals 4-16 years old. It consists of 10 questions assessing impact of skin diseases on different aspects of a patient's QoL over the prior week. The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item is scored on a 4-point scale (0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much). Item scores (0 to 3) are added to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL. A negative change from Baseline indicates improvement. In this study, the CDLQI was administered to participants who were \< 16 years old at the Baseline visit. LS means were calculated from ANCOVA with Baseline and treatment in the model.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in CDLQI Score at Week 28 and Week 52
score on a scalePlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 28——1.0 ± 0.00—
SecondaryChange From Baseline in Worst Pruritus Numerical Rating Scale at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Worst Pruritus Numerical Rating Scale at Week 16
score on a scalePlaceboRisankizumab 150 mgRisankizumab 300 mg
Change From Baseline in Worst Pruritus Numerical Rating Scale at Week 16-0.098 ± 0.5110-1.416 ± 0.3408-1.746 ± 0.3619
Statistical analysis
  • Placebo vs Risankizumab 150 mg · Mixed Effect Model Repeated Measurement · p = 0.033 · Ls mean difference: -1.318 · 95% CI -2.531 to -0.105Between Group Difference = Risankizumab - Placebo
  • Placebo vs Risankizumab 300 mg · Mixed Effect Model Repeated Measurement · p = 0.009 · Ls mean difference: -1.648 · 95% CI -2.885 to -0.411Between Group Difference = Risankizumab - Placebo
SecondaryChange From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Change from Baseline was calculated from a rolling weekly average. A negative change from Baseline indicates improvement. LS means and standard errors were calculated from an ANCOVA with Baseline, treatment and stratum (Baseline vIGA-AD categories) in the model.

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52
score on a scalePlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 28-2.685 ± 0.9303-3.182 ± 1.2347-2.474 ± 0.3887-2.684 ± 0.4179
Week 52-2.668 ± 1.2153-4.012 ± 1.3907-2.936 ± 0.4567-2.454 ± 0.4957
SecondaryPercentage of Participants Who Achieved a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Weeks 28 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS Score at Week 28 and Week 52
percentage of participantsPlacebo / Risankizumab 150 mgPlacebo / Risankizumab 300 mgRisankizumab 150 mg / Risankizumab 150 mgRisankizumab 300 mg / Risankizumab 300 mg
Week 2822.2 (0.0 to 49.4)20.0 (0.0 to 55.1)31.3 (18.1 to 44.4)39.5 (24.9 to 54.1)
Week 5220.0 (0.0 to 55.1)25.0 (0.0 to 67.4)38.2 (21.9 to 54.6)28.1 (12.5 to 43.7)

Adverse events

Collected over From first dose of study drug up to 20 weeks after last dose. Period A: 16 weeks for participants who entered Period B or up to 36 weeks for participants who did not enter Period B. Period B: From Week 16 up to Week 60.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period A: Placebo1/34 (2.9%)3/34 (8.8%)17/34 (50%)
Period A: Risankizumab 150 mg0/69 (0%)0/69 (0%)25/69 (36.2%)
Period A: Risankizumab 300 mg0/69 (0%)0/69 (0%)25/69 (36.2%)
Period B: Placebo / Risankizumab 150 mg0/13 (0%)0/13 (0%)6/13 (46.2%)
Period B: Placebo / Risankizumab 300 mg0/11 (0%)0/11 (0%)5/11 (45.5%)
Period B: Risankizumab 150 mg / Risankizumab 150 mg0/61 (0%)2/61 (3.3%)13/61 (21.3%)
Period B: Risankizumab 300 mg / Risankizumab 300 mg0/57 (0%)3/57 (5.3%)10/57 (17.5%)
Most frequent serious events
Most frequent serious events
EventPeriod A: PlaceboPeriod A: Risankizumab 150 mgPeriod A: Risankizumab 300 mgPeriod B: Placebo / Risankizumab 150 mgPeriod B: Placebo / Risankizumab 300 mgPeriod B: Risankizumab 150 mg / Risankizumab 150 mgPeriod B: Risankizumab 300 mg / Risankizumab 300 mg
COVID-19Infections and infestations1/340/690/690/130/110/610/57
CERVIX CARCINOMA STAGE INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/340/690/690/130/110/610/57
DERMATITIS ATOPICSkin and subcutaneous tissue disorders1/340/690/690/130/110/610/57
AMAUROSIS FUGAXEye disorders0/340/690/690/130/110/611/57
CELLULITISInfections and infestations0/340/690/690/130/111/611/57
FRACTURED COCCYXInjury, poisoning and procedural complications0/340/690/690/130/110/611/57
SPINAL FRACTUREInjury, poisoning and procedural complications0/340/690/690/130/110/611/57
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/340/690/690/130/110/611/57
ARRHYTHMIACardiac disorders0/340/690/690/130/111/610/57
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPeriod A: PlaceboPeriod A: Risankizumab 150 mgPeriod A: Risankizumab 300 mgPeriod B: Placebo / Risankizumab 150 mgPeriod B: Placebo / Risankizumab 300 mgPeriod B: Risankizumab 150 mg / Risankizumab 150 mgPeriod B: Risankizumab 300 mg / Risankizumab 300 mg
DERMATITIS ATOPICSkin and subcutaneous tissue disorders7/3419/6916/692/131/117/615/57
TOOTHACHEGastrointestinal disorders0/340/691/690/132/110/610/57
LEUKOPENIABlood and lymphatic system disorders0/341/690/690/131/111/610/57
BUNDLE BRANCH BLOCK RIGHTCardiac disorders0/340/690/690/131/110/610/57
DENTAL CARIESGastrointestinal disorders0/341/690/690/131/110/610/57
TOOTH INFECTIONInfections and infestations0/340/690/690/131/110/611/57
BLOOD THYROID STIMULATING HORMONE INCREASEDInvestigations0/340/690/690/131/110/610/57
DIZZINESS POSTURALNervous system disorders0/340/690/690/131/110/610/57
AMENORRHOEAReproductive system and breast disorders0/340/690/690/131/110/610/57
HYPERTROPHIC SCARSkin and subcutaneous tissue disorders0/340/690/690/131/110/610/57

Baseline characteristics

The intent-to-treat population includes all randomized participants

Age, Continuous
Age, Continuous(years)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
Mean45.5 ± 19.6641.7 ± 15.1243.8 ± 16.6343.3 ± 16.66
Age, Customized
Age, Customized(Participants)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
< 18 years0112
18 - 39 years15342776
40 - 64 years10273673
≥ 65 years97521
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
Female13313276
Male21383796
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
Hispanic or Latino08614
Not Hispanic or Latino346163158
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
White17393692
Black or African American781126
Asian8212049
Native Hawaiian or Other Pacific Islander1012
American Indian or Alaska Native0112
Multiple1001
Geographic Region
Geographic Region(Participants)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
Japan6131332
Rest of World285656140
Disease Severity
Disease Severity(Participants)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
3 (Moderate)20403999
4 (Severe)14293073
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(score on a scale)PlaceboRisankizumab 150 mgRisankizumab 300 mgTotal
Mean30.85 ± 12.34531.06 ± 13.99528.70 ± 11.24730.07 ± 12.605
09

Study locations

65 sites
  • UAB Department of Dermatology /ID# 211561
    Birmingham, Alabama 35233, United States
  • Cognitive Clinical Trials /ID# 208895
    Scottsdale, Arizona 85258-4446, United States
  • Cosmetic Dermatology of Orange County /ID# 205801
    Anaheim, California 92807-4780, United States
  • Center for Dermatology Clinical Research /ID# 204950
    Fremont, California 94538, United States
  • Integrative Skin Science and Research /ID# 212486
    Sacramento, California 95815-4500, United States
  • Cosmetic Laser Dermatology /ID# 210560
    San Diego, California 92121-2119, United States
  • Therapeutics Clinical Research /ID# 203422
    San Diego, California 92123, United States
  • Colorado Center for Dermatology, PLLC /ID# 216260
    Centennial, Colorado 80111-1724, United States
  • Park Avenue Dermatology, PA /ID# 203378
    Orange Park, Florida 32073, United States
  • MetroDerm ACC Research /ID# 205958
    Atlanta, Georgia 30342-1418, United States
  • Skin Care Physicians of Georgia /ID# 213188
    Macon, Georgia 31217, United States
  • University Dermatology and Vein Clinic, LLC /ID# 210702
    Darien, Illinois 60561, United States
  • The Indiana Clinical Trials Center /ID# 211618
    Plainfield, Indiana 46168, United States
  • Tulane University /ID# 203214
    New Orleans, Louisiana 70112-2699, United States
  • DermAssociates /ID# 206189
    Rockville, Maryland 20850, United States
  • Oakland Hills Dermatology /ID# 217453
    Auburn Hills, Michigan 48326-4600, United States
  • Duplicate_Great Lakes Research, Inc. /ID# 206447
    Bay City, Michigan 48602, United States
  • Grekin Skin Institute /ID# 210485
    Warren, Michigan 48088, United States
  • Skin Cancer and Dermatology Institute (SCDI) /ID# 213041
    Reno, Nevada 89052, United States
  • Psoriasis Treatment Center of Central New Jersey /ID# 203203
    East Windsor, New Jersey 08520, United States
  • Darst Dermatology /ID# 215100
    Charlotte, North Carolina 28277, United States
  • Dermatologists of Southwest Ohio, Inc /ID# 215104
    Mason, Ohio 45040-4520, United States
  • Unity Clinical Research /ID# 217461
    Oklahoma City, Oklahoma 73118, United States
  • Oregon Derm & Res. Ctr /ID# 202880
    Portland, Oregon 97210, United States
  • Dermatologic SurgiCenter /ID# 208972
    Drexel Hill, Pennsylvania 19026-1101, United States
  • Dermdox Dermatology Centers, PC /ID# 212259
    Hazleton, Pennsylvania 18201, United States
  • University of Pittsburgh MC /ID# 203296
    Pittsburgh, Pennsylvania 15260, United States
  • Derm Assoc of Plymouth Meeting /ID# 208925
    Plymouth Meeting, Pennsylvania 19462, United States
  • RI SkinDoc /ID# 203417
    Johnston, Rhode Island 02910-4423, United States
  • Omega Medical Research /ID# 216022
    Warwick, Rhode Island 02886, United States
  • Health Concepts /ID# 203205
    Rapid City, South Dakota 57702, United States
  • Rivergate Dermatology & Skin Care Center /ID# 203372
    Goodlettsville, Tennessee 37072-2301, United States
  • Arlington Research Center, Inc /ID# 215899
    Arlington, Texas 76011, United States
  • Tekton Research, Inc. /ID# 211558
    Austin, Texas 78745, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 203383
    Houston, Texas 77004-8097, United States
  • Acclaim Dermatology /ID# 213026
    Sugar Land, Texas 77479-2645, United States
  • Virginia Dermatology & Skin Cancer Center /ID# 210154
    Norfolk, Virginia 23502-2233, United States
  • Dominion Medical Associates /ID# 212986
    Richmond, Virginia 23219, United States
  • The Vancouver Clinic, INC. PS /ID# 202930
    Vancouver, Washington 98664, United States
  • Woden Dermatology /ID# 204778
    Phillip, Australian Capital Territory 2606, Australia
  • St George Hospital /ID# 204780
    Kogarah, New South Wales 2217, Australia
  • Veracity Clinical Research /ID# 204786
    Woolloongabba, Queensland 4102, Australia
  • North Eastern Health Specialists /ID# 204785
    Hectorville, South Australia 5073, Australia
  • Skin Health Institute Inc /ID# 204779
    Carlton, Victoria 3053, Australia
  • Fremantle Dermatology /ID# 204784
    Fremantle, Western Australia 6160, Australia
  • Kirk Barber Research, CA /ID# 201046
    Calgary, Alberta T2G 1B1, Canada
  • Beacon Dermatology Inc /ID# 213003
    Calgary, Alberta T3E 0B2, Canada
  • University of Alberta Hospital - Division of Hematology /ID# 213008
    Edmonton, Alberta T6G 2B7, Canada
  • Dr. Wei Jing Loo Medicine Prof /ID# 208849
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc. /ID# 201050
    Markham, Ontario L3P 1X2, Canada
  • Medicor Research Inc /ID# 211274
    Sudbury, Ontario P3A 1W8, Canada
  • Dre Angelique Gagne-Henley M.D. inc. /ID# 208189
    Saint-Jerome, Quebec J7Z 7E2, Canada
  • Japan Organization of Occupational Health and Safety Chubu Rosai Hospital /ID# 213667
    Nagoya-shi, Aichi 455-8530, Japan
  • Kurume University Hospital /ID# 203139
    Kurume-shi, Fukuoka 830-0011, Japan
  • Nippon Medical School Musashi Kosugi Hospital /ID# 213961
    Kawasaki-shi, Kanagawa 211-8533, Japan
  • Nagaoka Red Cross Hospital /ID# 214140
    Nagaoka-shi, Niigata 940-2085, Japan
  • University of the Ryukyus Hospital /ID# 203974
    Nakagami-gun, Okinawa 903-0215, Japan
  • Osaka City University Hospital /ID# 203410
    Osaka-shi, Osaka 545-8586, Japan
  • Hamamatsu University Hospital /ID# 203270
    Hamamatsu-shi, Shizuoka 431-3192, Japan
  • Teikyo University Hospital /ID# 202884
    Itabashi-ku, Tokyo 173-8606, Japan
  • Tokyo Medical University Hospital /ID# 203647
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Tokyo Medical University Hospital /ID# 204101
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Dr. Samuel Sanchez PSC /ID# 213117
    Caguas, 00727, Puerto Rico
  • Cruz-Santana, Carolina, PR /ID# 213229
    Carolina, 00985, Puerto Rico
  • Clinical Research Puerto Rico /ID# 213118
    San Juan, 00909, Puerto Rico
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Oct 2020, 22 months.

Results were first posted in Nov 2021, 1 year after primary completion.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 22 months is above that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2018
First posted
Oct 15, 2018
StartActual
Dec 27, 2018
Primary completionActual
Oct 28, 2020
CompletionActual
Apr 26, 2021
Results first posted
Nov 18, 2021
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03706040
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 15, 2018
Start date
Dec 27, 2018
Primary completion
Oct 28, 2020
Completion
Apr 26, 2021
Results posted
Nov 18, 2021
Last update
Nov 18, 2021

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion